T1	Premise 1297 1455	The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063).
T2	Premise 1460 1592	The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)
T3	Claim 1687 1818	The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen.
T5	Claim 1867 2033	It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC.
R1	Support Arg1:T5 Arg2:T3	
T4	Premise 1593 1682	except cognitive and social functions, the symptoms of dysphagia and pain in other parts.
R2	Partial-Attack Arg1:T4 Arg2:T2	
R3	Support Arg1:T1 Arg2:T3	
T6	Claim 1819 1862	It was advantageous over improving the QOL.
R4	Support Arg1:T2 Arg2:T6	
